(Total Views: 474)
Posted On: 11/06/2021 12:05:25 PM
Post# of 155138
Thanks!
The paper says that downstream action of the LZTFL1 causes an increase of CEBPB (an immune regulator). They mention three possible receptors that may be affected none of which are CCR5 which is curious. CEBPB binds to IL-1, IL-6 and other inflammatory cytokines. It also increases collagen production, IL-4, IL-5, IL-6 and TNF-a. All of which are downregulated by leronlimab. CEBPB also increases the expression of CCR5.
Of note is that some types of cancer tumors also increase the expression of CEBPB.
The paper says that downstream action of the LZTFL1 causes an increase of CEBPB (an immune regulator). They mention three possible receptors that may be affected none of which are CCR5 which is curious. CEBPB binds to IL-1, IL-6 and other inflammatory cytokines. It also increases collagen production, IL-4, IL-5, IL-6 and TNF-a. All of which are downregulated by leronlimab. CEBPB also increases the expression of CCR5.
Of note is that some types of cancer tumors also increase the expression of CEBPB.
(3)
(0)
